略歴：

1986年名古屋大学医学部卒業、その後、大阪大学微生物病研究所助手、名古屋大学医学部分院内科講師を経て、2007年11月末まで東海大学医学部腎・代謝内科学教授、総合医学研究所所長。

現職：

東北大学大学院医学系研究科　教授・研究科長特別補佐（研究・産学連携担当）

兼務：

・ベルギー王室アカデミー　生涯会員

・国立研究開発法人 日本医療研究開発機構「先端バイオ創薬等基盤技術開発事業」

　プログラムスーパーバイザー

・内閣官房健康・医療戦略室：医薬品開発協議会　委員

・文部科学省　ライフサイエンス委員

・厚生労働省　革新的医薬品・医療機器創出のための官民対話　委員

Takahashi N, Kameoka Y, Onizuka M, Onishi Y, Takahashi F, Miyata T, Ando K, Harigae H. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor. Cancer Medicine 2023; 12: 4250-4258.

Sun T, Ghosh AK, Eren M, Miyata T, Vaughan DE. PAI-1 contributes to homocysteine-induced cellular senescence. Cellular Signalling 2019; 64: 109394.

Ghosh AK, Soberanes S, Lux E, Shang M, Aillon RP, Eren M, Budinger GRS, Miyata T, Vaughan DE. Pharmacological inhibition of PAI-1 alleviates cardiopulmonary pathologies induced by exposure to air pollutants PM2.5. Environ Pollut. 2021; 287: 117283.　

最近の業績：

Levine J A, Oleaga C, Mesut E, Amaral Ansel P, Shang M, Lux E, Khan S S, Shah S J, Omura Y, Pamir N, Hay J, Barish G, Miyata T, Tavori H, Fazio S & Vaughan D E. Role of PAI-1 in hepatic steatosis and dyslipidemia. Scientific Report 2021; 11: 430.

Hirai S , Miwa H , Tanaka T , Toriumi K , Kunii Y , Shimbo H , Sakamoto T , Hino M, IzumiR, Nagaoka A, Yabe Y, Nakamachi T, Shioda S, Dan T,  Miyata T, Nishito Y , Suzuki K , Miyashita M , Tomoda T, Hikida T, Horiuchi J, Itokawa M, Arai M, Okado H. High-sucrose diets contribute to brain angiopathy with impaired glucose uptake and psychosis-related higher brain dysfunctions in mice. Science Advances 2021; 7: 6077.

Toriumi K, Berto S, Koike K, Usui K, Dan T, Suzuki K, Miyashita M, Horiuchi Y, Yoshikawa A, Sugaya Y, Watanabe T, Asakura M, Kano M, Ogasawara Y, Miyata T, Itokawa M, Konopka G, Arai M. Combined glyoxalase 1 dysfunction and vitamin B6 deficiency in a schizophrenia model system causes mitochondrial dysfunction in the prefrontal cortex. Redox Biology 2021; 45: 102057.

Harada K, Yahata T, Onizuka M, Ibrahim A.A, Kikkawa E, Miyata T, Ando K. Plasminogen activator inhibitor type-1 is a negative regulator of hematopoietic　regeneration in the adipocyte-rich bone marrow microenvironment. Biochem Biophys Res Commun. 2021; 557: 180-186.

Koike S, Toriumi K, Kasahara S, Kibune Y, Ishida Y,Dan T, Miyata T, Arai M, Ogasawara Y. Accumulation of Carbonyl Proteins in the Brain of Mouse Model for Methylglyoxal Detoxification Deficits.  Antioxidants 2021; 10: 574.

Sillen M, Miyata T , Vaughan DE , Strelkov SV and Declerck PJ.  Structural insight into the two-step mechanism of PAI-1 inhibition by small molecule TM5484. Int J Mol Sci. 2021; 22: 1482.

Levine J A, Oleaga C, Mesut E, Amaral Ansel P, Shang S, Lux E, Khan S S, Shah S J, Omura Y, Pamir N, Hay J, Barish G, Miyata T, Tavori H, Fazio S & Vaughan D E. role of PAI‑1 in hepatic steatosis and dyslipidemia. Scientific Reports 2021; 11: 430.

Nakayama M, Hamada C, Yokoyama K, Tanno Y, Matsuo N, Nakata J, Ishibashi Y, Okuzawa A, Sakamoto K, Nara T, Kakuta T, Nangaku M, Yokoo T, Suzuki Y, Miyata T. A disposable, ultra‑fine endoscope for non‑invasive, close examination of the intraluminal surface of the peritoneal dialysis catheter and peritoneal cavity. Scientific Reports. 2020;10: 17565.

Imai J, Yahata T, Ichikawa, Ibrahim A.A , Yazawa M, Sumiyoshi H, Inagaki Y, Matsushima M, Suzuki T, Mine T, Ando K, Miyata T, Hozumi K. Inhibition of plasminogen activator inhibitor-1 attenuates against intestinal fibrosis in mice. Intestinal Research 2020; 18: 219-228.

Rana T, Jiang C, Liu G, Miyata T, Antony V, Thannickal VJ, Liu RM. PAI-1 Regulation  of TGF-β1-induced ATII Cell Senescence, SASP Secretion, and SASP-mediated Activation of Alveolar Macrophages. Am J Respir Cell Mol Biol. 2020; 62: 319-330. 

Henkel AS, Khan SS, Olivares S, Miyata T, Vaughan DE. Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice. Hepatol Commun. 2018; 2: 1479-1492.

Akhter H, Huang WT, van Groen T, Kuo HC, Miyata T,, Liu RM. A Small Molecule Inhibitor of Plasminogen Activator Inhibitor-1 Reduces Brain Amyloid-β Load and Improves Memory in an Animal Model of Alzheimer's Disease. Journal of Alzheimer’s Disease. 2018; 64: 447-457.

Itokawa M, Miyashita M, Arai M, Dan T, Takahashi K, Tokunaga T, Ishimoto K, Toriumi K, Ichikawa T, Horiuchi Y, Kobori A, Usami S, Yoshikawa T, Amano N, Washizuka S, Okazaki Y, Miyata T. Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress. Psychiatry Clin Neurosci. 2018; 72: 35-44.

Khan SS, Shah SJ,Klyachko E, Baldridge AS, Eren M, Place AT, Aviv A, Puterman E, Lloyd-Jones DM, Heiman M, Miyata T, Gupta S, Shapiro AD, Vaughan DE. A null mutation in SERPINE1 protects against biological aging in humans. Science Advances 2017; 3: 1617.

Yahata T, Ibrahim A.A, Muguruma Y, Eren M, Shaffer AM, Watanabe N, Kaneko S, Nakabayashi N, Dan T, Hirayama N, Vaughan DE, Miyata T, Ando K. TGF-β-induced intracellular PAI-1 is responsible for retaining   hematopoietic stem cells in the niche. Blood. 2017; 130: 2283-2294.

Eren M, Place AT, Thomas PM, Flevaris P, Miyata T, Vaughan DE. PAI-1 is a critical regulator of FGF23 homeostasis. Science Advances 2017; 3: e1603259

Honjo T, Munakata S, Tashiro Y, Salama Y, Shimazu H, Eiamboonsert S, Dhahri D, Ichimura A, Dan T, Miyata T, Takeda K, Sakamoto K, Hattori K, Heissig B. Plasminogen activator inhibitor-1 regulates macrophage-dependent postoperative adhesion by enhancing EGF-HER1 signaling in mice. FASEB J. 2017; 31: 2625-2637.

Ghosh AK, Rai R, Park KE, Eren M, Miyata T, Wilsbacher LD, Vaughan DE. A small molecule inhibitor of PAI-1 protects against Doxorubicin-induced cellular senescence: molecular basis. Oncotarget 2016; 7: 72443-72457.

Liu RM, Eldridge S, Watanabe N, Deshane J, Kuo HC, Jiang C, Wang Y, Liu G, Schwiebert L, Miyata T, Thannickal VJ. Therapeutic potential of an orally effective small molecule inhibitor of plasminogen activator inhibitor for asthma. Am J Physiol Lung Cell Mol Physiol. 2016; 15: 328-336.

Jeong BY, Uddin MJ, Park JH, Lee JH, Lee HB, Miyata T, Ha H. Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model. PLoS One. 2016; 11: e0157012.

Piao L,Jung I, Huh JY,  Miyata T, Ha H. A novel plasminogen activator inhibitor-1 inhibitor, TM5441, protects against high-fat diet-induced obesity and adipocyte injury in mice. British J Pharmacology. 2016; 173: 2622-2632.

Maessen DE, Brouwers O, Gaens KH, Wouters K, Cleutjens JP, Janssen BJ, Miyata T, Stehouwer CD, Schalkwijk CG. Delayed intervention with pyridoxamine improves metabolic function and prevents adipose tissue inflammation and insulin resistance in high-fat diet-induced obese mice. Diabetes 2016; 65: 956-966.

Placencio VR, Ichimura A, Miyata T, DeClerck YA. Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity. PLoS One 2015; 10: e0133786.

Souma T, Nezu M, Nakano D, Yamazaki S, Hirano I, Sekine H, Dan T, Takeda K, Fong GH, Nishiyama A, Ito S, Miyata T, Yamamoto M, Suzuki N. Erythropoietin Synthesis in Renal Myofibroblasts Is Restored by Activation of Hypoxia Signaling. J Am Soc Nephrol. 2016; 27: 428-438.

Pelisch N, Dan T, Ichimura A, Sekiguchi H, Vaughan DE, van Ypersele de Strihou C, Miyata T. Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis. PLoS One 2015; 10: e0124510.

Kobayashi N, Ueno T, Ohashi K, Yamashita H, Takahashi Y, Sakamoto K, Manabe S, Hara S, Takashima Y, Dan T, Pastan I, Miyata T, Kurihara H, Matsusaka T, Reiser J, Nagata M. Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via beta 1 integrin endocytosis. Am J Physiol Renal Physiol. 2015; 308: F614-26.

Boe AE, Eren M, Morales-Nebreda L, Murphy SB, Budinger GR, Mutlu GM, Miyata T, Vaughan DE. Nitric oxide prevents alveolar senescence and emphysema in a mouse model. PLoS One 2015; 10: e0116504.

Eren M, Boe A, Murphy SB, Place AT,  Nagpal V, Morales-Nebreda L, Urich D, Quaggin SE, Budinger GS, Mutlu GM, Miyata T, Vaughan DE. PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice.

Proc Natl Acad Sci USA. 2014; 111: 7090-7095.

Miyata T, Ando T, Hiragi H, Watanabe K, Yamamoto F, Vaughan DE, Kurokawa T, Oshima Y, van Ypersele de Strihou C, Takeuchi M. Drug discovery in renal disease —towards a more efficient framework. Nature Review. 2014; 10: 290-296.

Ibrahim A.A, Yahata T, Onizuka M, Dan T, van Ypersele de Strihou C, Miyata T, Ando K. Inhibition of Plasminogen Activator Inhibitor Type-1 Activity Enhances Rapid and Sustainable Hematopoietic Regeneration. Stem Cells 2014; 32: 946-58.

Brouwers O, Niessen PM, Miyata T, Østergaard JA, Flyvbjerg A, Peutz-Kootstra CJ, Sieber J, Mundel PH, Brownlee M, Janssen BJ, De Mey JG, Stehouwer CD, Schalkwijk CG. Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model

of diabetes. Diabetologia 2014; 57: 224-235.

Boe A, Eren M, Murphy S, Kamide1 C, Ichimura A, Terry D, McAnally D, Smith LH, Miyata T, Vaughan DE. The PAI-1 antagonist TM5441 attenuates L-NAME-induced hypertension and vascular senescence. Circulation 2013; 128: 2318-2324.

Remuzzi G, Benigni A, Finkelstein FO, Grunfeld JP, Joly D, Katz I, Liu ZH, Miyata T, Perico N, Rodriguez-Iturbe B, Antiga L, Schaefer F, Schieppati A, Schrier RW, Tonelli M. Kidney failure: aims for the next 10 years and barriers to success. Lancet 2013; 382: 353-362.

Miyata T, Suzuki N, van Ypersele de Strihou C. Diabetic nephropathy: Are there new and potentially promising therapies targeting oxygen biology?

Kidney Int. 2013; 84: 693-702.

Ichimura A, Matsumoto S, Suzuki S, Dan T, Yamaki S, Sato Y, Kiyomoto H, Ishii N, Okada K, Matsuo O, Hou FF, Vaughan DE, van Ypersele de Strihou C, Miyata T. A Small Molecule Inhibitor to Plasminogen Activator Inhibitor 1 Inhibits Macrophage Migration. Arterioscler Thromb Vasc Biol. 2013; 33: 935-942.

Shanab AY, Nakazawa T, Ryu M, Tanaka Y, Himori N, Taguchi K, Yasuda M, Watanabe R, Takano J, Takaomi S, Minegishi N, Miyata T, Abe T, Yamamoto M. Metabolic stress response implicated in diabetic retinopathy:the role of calpain, and the therapeutic impact of calpain inhibitor. Neurobiology of Disease 2012; 48: 556-567. 

Zhou LL, Cao W, Xie C, Tian J, Zhou Z, Zhou Q, Zhu P, Li A, Liu Y, Miyata T, Hou FF, Nie J. The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int 2012; 82: 759-770. 

Tashiro Y, Nishida C, Sato-Kusubata K, Ohki-Koizumi M, Ishihara M, Sato A, Gritli I, Komiyama H, Sato Y, Dan T, Miyata T, Okumura K, Tomiki Y, Sakamoto K, Nakauchi H, Heissig B, Hattori K. Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice. Blood. 2012; 119: 6382-6393.

Berner AK, Brouwers O, Pringle R, Klaassen I, Colhoun L, McVicar C, Brockbank S, Curry JW, Miyata T, Brownlee M, Schlingemann RO, Schalkwijk C, Stitt AW. Protection against methylglyoxal-derived AGEs by regulation of glyoxalse-1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia. 2012; 55: 845-854.

Momma H, Niu K, Kobayashi Y, Guan L, Sato M, Guo H, Chujo M, Otomo A, Yufei C, Tadaura H, Saito T, Mori T, Miyata T, Nagatomi R. Skin advanced glycation end product accumulation is negatively associated with calcaneal osteo-sono assessment index among non-diabetic adult Japanese men. Osteoporos Int. 2012; 23: 1673-1681.

Huang WT, Vayalil PK, Miyata T, Hagood J, Liu RM. Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis. Am J Respir Cell Mol Biol. 2012; 46: 87-95.

Ikeda Y, Inagi R, Miyata T, Nagai R, Arai M, Miyashita M, Itokawa M, Fujita T, Nangaku M. Glyoxalase I retards renal senescence. Am J Pathol. 2011; 179: 2810-2821.

Miyata T, Kikuchi K, Kiyomoyo H,van Ypersele de Strihou C. New era for drug discovery and development in renal disease. Nature Review. 2011; 7: 469-477.

Miyata T, Eckardt KU, Nangaku M. Oxidative Stress in Applied Basic Research and Clinical Practice: Studies on Renal Disorders (Springer)

Miyata T, Takizawa S, van Ypersele de Strihou C. Hypoxia. 1.Intracellular sensors for oxygen and oxidative stress: Novel therapeutic targets. Am J Physiol Cell Physiol. 2011; 300: 226-231.

Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, Takahashi H, Hirawa N, Oogushi Y, Miyata T, Kobayashi H, Fukagawa M, Saito A. Effect of Sevelamer and Calcium-Based Phosphate Binders on Coronary Artery Calcification and Accumulation of Circulating Advanced Glycation End Products in Hemodialysis Patients. Am J Kidney Dis. 2011; 57: 422-431.

Brouwers O, Niessen PM, Ferreira I, Miyata T, Scheffer PG, Teerlink T, Schrauwen P, Brownlee M, Stehouwer CD, Schalkwijk CG. Overexpression of Glyoxalase-I Reduces Hyperglycemia–induced Levels of Advanced Glycation Endproducts and Oxidative Stress in Diabetic Rats. J Biol Chem. 2011; 286: 1374-1380.

Arai M, Yuzawa H, Nohara I, Ohnishi T, Obata N, Iwayama Y, Haga S, Toyota T, Ujike H, Arai M, Ichikawa T, Nishida A,Tanaka Y, Furukawa A, Aikawa Y, Kuroda O, Niizato K, Izawa R, Nakamura K, Mori N, Matsuzawa D, Hashimoto K, Iyo M, Sora I, Matsushita M, Okazaki Y, Yoshikawa T, Miyata T, Itokawa M.  Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch Gen Psychiatry. 2010; 67: 589-597.

Miyata T, van Ypersele de Strihou C. Diabetic nephropathy: a disorder of oxygen metabolism? Nature Review. 2010; 6: 83-95.